Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Neutralizing antibodies do not fully explain SARS-CoV-2 protective immunity

Nature Medicine (2024)Cite this article

Subjects

Based on two population cohorts in South Africa, we established neutralizing antibodies in serum as correlates of protection against SARS-CoV-2 Delta and Omicron variants for immunity induced by previous infection. We further quantified the relative contribution of neutralizing antibodies to the overall protection conferred by prior infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Distribution of neutralizing antibody titers in sera collected prior to SARS-CoV-2 Delta and Omicron waves.

References

  1. Gilbert, P. B. et al. A Covid-19 milestone attained — a correlate of protection for vaccines. N. Engl. J. Med. 387, 22032206 (2022). A prospective article that summarizes the success of establishing a SARS-CoV-2 correlate of protection before the emergence of immune-evasive variants.

    Article  Google Scholar 

  2. Mettelman, R. C. et al. Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology. Nat. Immunol. 24, 1511–1526 (2023). This paper reports the contribution of innate and adaptive cellular responses, as well as pre-existing antibodies, to protection against influenza virus.

    Article  CAS  PubMed  Google Scholar 

  3. Cohen, C. et al. Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study. Lancet Glob. Health 9, e863–e874 (2021). This paper reports the pre-pandemic PHIRST cohort infrastructure that this study relies on.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cowling, B. J. et al. Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. Clin. Infect. Dis. 68, 1713–1717 (2019). A pioneer study adopting mediation analysis to understand correlates of protection against influenza B virus.

    Article  CAS  PubMed  Google Scholar 

  5. Halloran, M. E. & Struchiner, C. J. Causal inference in infectious diseases. Epidemiology 6, 142–151 (1995). A seminal paper that proposed using transmission probability as a causal estimand for causal inference in infectious disease.

    Article  CAS  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Sun, K. et al. SARS-CoV-2 correlates of protection from infection against variants of concern. Nat. Med. https://doi.org/10.1038/s41591-024-03131-2 (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neutralizing antibodies do not fully explain SARS-CoV-2 protective immunity. Nat Med (2024). https://doi.org/10.1038/s41591-024-03168-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41591-024-03168-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing